Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid TumorsToshio Shimizu, Anthony W. Tolcher, K. Papadopoulos et al.|Clinical Cancer Research|2014Cited by 82